Immunotherapy – Page 3

IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck

7 months ago talkbio0Tagged biotech, Cancer Vaccines, Head and neck structure, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Phase 2 trial, Squamous cell carcinoma, Squamous cell carcinoma of the head and neck

IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy

ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer

7 months ago talkbio0Tagged biotech, Cancer of Neck, Congress (U.S. Legislature), ESMO, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Therapeutic Cancer Vaccine

IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy

AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches

8 months ago talkbio0Tagged AstraZeneca, Biological Markers, Immunotherapy, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma

NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment

ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges

8 months ago talkbio0Tagged Agonist, Anktiva, Approved, Cancer Therapeutic Procedure, financial troubles, ImmunityBio, Immunotherapy, Interleukin-15, United States Food and Drug Administration

ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy

UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development

8 months ago talkbio0Tagged California, development aspects, Gary Michelson, Immunology, Immunotherapy, research, Ucla, Vaccines

UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

8 months ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million

9 months ago talkbio0Tagged Capital, central venous catheter (CVC) sets, Immunotherapy, mallinckrodt

Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

9 months ago talkbio0Tagged Capital Partners, central venous catheter (CVC) sets, Extracorporeal, Healthcare services, Immunotherapy, Lymphoma, T-Cell, Cutaneous, mallinckrodt, medical technology, Photopheresis, RNASE3 gene, Therakos

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services